U.S. News Room
Mon Dec 22 00:00:00 GMT-05:00 2025
NEW
ENHERTU Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Download
Mon Dec 22 00:00:00 GMT-05:00 2025
NEW
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Download
Mon Dec 15 00:00:00 GMT-05:00 2025
NEW
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
Tue Dec 09 00:00:00 GMT-05:00 2025
NEW
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Download
Mon Dec 08 00:00:00 GMT-05:00 2025
NEW
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
Download
Wed Dec 03 00:00:00 GMT-05:00 2025
NEW
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Download
Mon Nov 10 00:00:00 GMT-05:00 2025
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
Thu Oct 30 00:00:00 GMT-05:00 2025
DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Download
Sun Oct 19 00:00:00 GMT-05:00 2025
DATROWAY Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Versus Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial
Download
Sun Oct 19 00:00:00 GMT-05:00 2025
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2,3 Trial
Download